Australia
Argenica confident FDA hurdles cleared
Perth neurological drug developer Argenica Therapeutics says it has addressed several hurdles that led the US FDA to pull back clinical trials of its flagship ARG-007 stroke drug.
Perth neurological drug developer Argenica Therapeutics says it has addressed several hurdles that led the US FDA to pull back clinical trials of its flagship ARG-007 stroke drug.
